Tirbanibulin

What Is Tirbanibulin?

• Tirbanibulin (KLISYRI) is a microtubule inhibitor indicated for the topical treatment of actinic keratosis of the face or scalp.

File:Tirbanibulin-line.png

What are the uses of this medicine?

Tirbanibulin (KLISYRI) is indicated for the topical treatment of actinic keratosis on the face or scalp.

How does this medicine work?

• Tirbanibulin is a microtubule inhibitor.
• The mechanism of action of KLISYRI for the topical treatment of actinic keratosis is unknown.
• An orally bioavailable small molecule Src kinase inhibitor with potential antineoplastic activity.
• Unlike other Src kinase inhibitors which bind to the ATP-binding site, tirbanibulin specifically binds to the peptide substrate binding site of Src kinase; inhibition of kinase activity may result in the inhibition of primary tumor growth and the suppression of metastasis.
• Src tyrosine kinases are upregulated in many tumor cells and play important roles in tumor cell proliferation and metastasis.

Who Should Not Use this medicine ?

• This medicine have no usage limitations

Is this medicine FDA approved?

• It was approved for use in the United States in 2020.

How should this medicine be used?

• For topical use only; not for oral or ophthalmic use.
• Apply sufficient amount of KLISYRI to evenly cover up to 25 cm2 treatment field on the face or scalp once daily for 5 consecutive days using 1 single-dose packet per application.
• Wash hands immediately with soap and water after application.
• Avoid washing and touching the treated area for approximately 8 hours after application of KLISYRI.
• Following this time, the area may be washed with a mild soap.
• Avoid transfer of KLISYRI to the periocular area.
• Avoid application near and around the mouth and lips.

What are the dosage forms and brand names of this medicine?

This medicine is available in fallowing doasage form:

• As an ointment: 1% white to off-white ointment in a single-dose packet (2.5 mg tirbanibulin in 250 mg).

This medicine is available in fallowing brand namesː

• KLISYRI

What side effects can this medication cause?

Common possible side effects of this medicine include:

• local skin reactions
• application site pruritus
• application site pain

What special precautions should I follow?

• Avoid transfer of the drug into the eyes and to the periocular area during and after application.
• Wash hands immediately after application.
• If accidental exposure occurs, instruct patient to flush eyes with water and seek medical care as soon as possible.
• Local skin reactions, including severe reactions (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation and erosion/ulceration) in the treated area can occur after topical application of KLISYRI.
• Avoid use until skin is healed from any previous drug, procedure, or surgical treatment.

What to do in case of emergency/overdose?

• Overdose of this medicine could cause an increase in incidence and severity of local skin reactions.

Can this medicine be used in pregnancy?

• There are no available data with KLISYRI use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.

Can this medicine be used in children?

• It is not known if KLISYRI is safe and effective in children less than 18 years of age.

What should I know about storage and disposal of this medication?

• Store at room temperature between 68°F to 77°F (20°C to 25°C) .
• Do not refrigerate or freeze.
• Safely throw away used KLISYRI packets in household trash.
• Keep KLISYRI and all medicines out of the reach of children.

This article is a stub. You can help WikiMD by registering to expand it. Editing is available only to registered and verified users. WikiMD is a comprehensive, free health & wellness encyclopedia.

• Dailymed label info on Tirbanibulin
• FDA Tirbanibulin